To be successful in the highly competitive pharmaceutical contract services market requires the passion to exceed customer expectations and the talent and drive to constantly perform at the highest levels.
Providing a Great Place to Work
The workplace culture at CDMOs must encourage the high level of passion and commitment to excellence and quality required to ensure that projects move from development to commercialization as quickly and cost-effectively as possible, yet with an assurance of high quality. At Dalton Pharma Services, we have created a high-trust and high-performance culture in which employees are valued and professional and personal development is encouraged. Employees are recognized for their individual contributions and encouraged to achieve a work–life balance. As a result, they are committed to completing even the most complex and challenging projects on time and on budget without compromising quality.
These efforts have been recognized by independent organizations. In May 2018, Dalton was named one of the Top 50 Best Workplaces™ in Canada by Great Place to Work®, a global research and consulting firm. For the last four years, we were also named a Great Place to Work® by Great Place to Work® Institute Canada. This recognition is based on direct feedback from employees.
Certification as a Great Workplace shows our commitment towards providing a culture of inclusion, diversity and fulfillment and a respectful work environment. It has also played a major role in attracting and retaining talented people from around the world. This diversity and the passion and ability of our people to deliver unmatched value to our clients have been significant contributors to our success.
Quality and compliance are the cornerstones for our business, as we strive to continuously improve our facilities and services.
Integrated Services Reduce Project Timelines
Dalton is a cGMP contract service provider of integrated chemistry, drug development and manufacturing services with more than 30 years of experience. Our GMP facility is licensed by Health Canada and was recently audited by the U.S. Food and Drug Administration (FDA) in January 2019.
We are experts in medicinal chemistry; process, formulation and analytical method development; route and process optimization; and cGMP API and solid and sterile finish dose manufacturing. We place an emphasis on quality, reliability, speed and flexibility — all at one centralized location. We move projects seamlessly from inception to cGMP manufacturing, simplifying client supply chains and reducing timelines and cost.
Recognition in the Form of Industry Leadership Awards
Development of novel medicines requires a highly interdisciplinary and technologically sophisticated group of professionals. Delivering for our clients demands a team with deep understanding of science and regulatory compliance, along with an innovative mindset. Our passionate, talented and committed employees have repeatedly demonstrated their ability to quickly move projects from concept to commercialization.
These efforts have been rewarded for three years in a row with the Life Sciences Leader CMO Leadership Award, which recognizes the highest quality contract manufacturing organizations as chosen by real customers, in five core categories: Reliability, Capabilities, Expertise, Compatibility and Quality.
Continual Improvement
At Dalton Pharma Services, quality and compliance are the cornerstones for our business, as we strive to continuously improve our facilities and services. We recently expanded our headcount by approximately three dozen, implemented a $10 million facility and capital expansion, including a fully automated Sterile Liquid Filling System that will become operational in Q3 of 2019 and acquired an inductively coupled plasma mass spectrometer (ICP-MS) system to comply with the updated ICH Q3D elemental impurities regulatory guidelines for drug products.
The new fill line allows larger batch sizes (~40 BPM) and a broader range of filling volumes and container closure systems and provides nitrogen purging and individual bottle serialization. It will increase our capacity by approximately 5-fold to 25,000–35,000 vials per batch. The flexibility that this new fill line provides will enable Dalton to extend services beyond the current clinical stage and accelerate the development of clients’ sterile drug products through commercial launch.
We are also in the initial stages of sourcing vendors for a new high-throughput, potentially robotically controlled sterile powder filling line that will increase our current fill range up to 25,000 vials per batch.
